Welldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes.
Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with insulin. For all participants and subgroups examined, time in range and the glucose management indicator (GMI) improved significantly, demonstrating that the combination could improve type 2 diabetes management and glycemic control.
The company combines the Dexcom G6 CGM with its BlueStar digital health platform, thanks to a partnership expansion agreed upon by the companies in April 2021. Three patient cohorts were evaluated with this combination, with data showing that the intermediate users’ cohort improved the most, increasing their time in range by 32% and GMI by 1.4.
BlueStar, an FDA-cleared software as a medical device offering, provides actionable insights that inform care plans and encourage better total health outcomes. Self-management behavior coaching on BlueStar includes parameters related to food, activity, sleep, symptoms and medication taking.
“We are encouraged by the improvements we observed in glycemic outcomes and believe the findings demonstrate the significant potential that real-time CGM data integration brings to our digital health offering,” Welldoc CMO Dr. Mansur E. Shomali said in a news release. “As we improve our understanding of digital health engagement needs in relation to CGM, we move closer toward a care model that captures ‘whole person care’ in ways not achieved to date.”
